Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction

Basit Öğe Kaydı
dc.authorid0000-0001-7858-0672en_US
dc.authorid0000-0002-4353-9538en_US
dc.contributor.authorÖztürk, Ufuk
dc.contributor.authorYeşil, Süleyman
dc.contributor.authorGöktuğ, Hasan Nedim Göksel
dc.contributor.authorGücük, Adnan
dc.contributor.authorTuygun, Can
dc.date.accessioned2021-06-23T19:35:39Z
dc.date.available2021-06-23T19:35:39Z
dc.date.issued2014
dc.departmentBAİBÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.description.abstractIt has been shown on experimental rat models that type 5-phosphodiesterase isoenzyme (PDE5) inhibitors have anti-fibrotic effects for Peyronie's disease (PD); however, this issue has not been addressed clinically. The aim of this study was to document the effects of PDE5 inhibitors used for erectile dysfunction (ED) seen in PD patients on the main course of the PD clinically. A total of 39 PD patients with ED were divided into two groups. Patients in Group 1 (n = 18) served as controls and received 400 IU vitamin E per day. Those in Group 2 (n = 21) received 50 mg sildenafil per day for 12 weeks. Penile plaque volume was assessed by palpation and by duplex ultrasound. Erectile capacity, penile deformity and plaque characteristics were assessed by the International Index of Erectile Function questionnaire form (IIEF-5) and penile duplex ultrasound. Statistically significant improvement in all parameters was observed within both groups except for IIEF score in Group 1 when compared with the initial values. Significant reduction in plaques and pain were observed in 7 (33.3 %) and 14 (66.6 %) patients in Group 2 and 6 (33.3 %) and 9 patients (42.8 %) in Group 1, respectively. At the end of the therapy, improvement in IIEF score and reduction in pain were statistically significant in Group 2 compared with Group 1 (p = 0.028 and p = 0.045, respectively). We conclude that continuous administration of oral PDE5 inhibitors may be a candidate for medical treatment of PD; however, more controlled studies are needed.en_US
dc.identifier.doi10.1007/s11845-013-1036-5
dc.identifier.endpage453en_US
dc.identifier.issn0021-1265
dc.identifier.issn1863-4362
dc.identifier.issue3en_US
dc.identifier.pmid24190613en_US
dc.identifier.scopus2-s2.0-84904424367en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage449en_US
dc.identifier.urihttps://doi.org/10.1007/s11845-013-1036-5
dc.identifier.urihttps://hdl.handle.net/20.500.12491/7837
dc.identifier.volume183en_US
dc.identifier.wosWOS:000339818300018en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorGücük, Adnan
dc.language.isoenen_US
dc.publisherSpringer London Ltden_US
dc.relation.ispartofIrish Journal Of Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPeyronie's Diseaseen_US
dc.subjectPhosphodiesterase Isoenzyme Inhibitorsen_US
dc.subjectSildenafilen_US
dc.subjectTreatmenten_US
dc.titleEffects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunctionen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
ufuk-ozturk.pdf
Boyut:
169.06 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/Full text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu